期刊文献+

5-氮杂脱氧胞苷联合孕激素对子宫内膜癌细胞株HEC-1-B生长的影响 被引量:1

Study on the effect of 5-Aza-CdR and progesterone on PR-B negative endometrial cancer cell lines HEC-1-B
下载PDF
导出
摘要 目的:研究5-氮杂脱氧胞苷(5-Aza-CdR,ADC)联合孕激素对孕激素受体B亚型(PR-B)缺失的子宫内膜癌细胞株HEC-1-B增殖、凋亡、细胞周期分布的影响及其机制。方法:5-Aza-CdR、醋酸甲羟孕酮(medroxyprogesterone acetate,MPA)单独及联合作用于HEC-1-B细胞后,运用MTT比色法及流式细胞仪分别检测各组细胞的生长、凋亡及细胞周期分布情况;采用RT-PCR技术、甲基化特异性PCR(MSP)分别检测HEC-1-B细胞中PR-B mRNA表达及PR-B基因启动子的甲基化状态。结果:(1)5-Aza-CdR对HEC-1-B细胞的生长抑制作用呈剂量和时间依赖性,联合用药组的抑制作用更为明显(P<0.01),且使细胞阻滞在G1期;(2)5-Aza-CdR以剂量依赖的方式上调PR-B mRNA的表达(P<0.01);(3)5-Aza-CdR可以抑制PR-B基因启动子的甲基化状态。结论:(1)5-Aza-CdR联合孕激素能明显抑制HEC-1-B细胞增殖,促进其凋亡,二者联用可加强MPA对细胞周期的阻滞作用;(2)5-Aza-CdR能逆转PR-B基因甲基化而使其恢复表达,从而增强孕激素的作用。 Objectives:To study the effect of 5-Aza-CdR combined with progesterone on proliferation of Endometrial cancer cell line HEC-1-B cells and hypermethylation of PR-B gene.Methods:The effect of 5-Aza-CdR and/or MPA on proliferation,apoptosis and cell cycle of HEC-1-B cell was separately studied by MTT and flow cytometry.The effect of 5-Aza-CdR on the expression and methylation status of PR-B gene of HEC-1-B cell was separately observed by RT-PCR and MSP.Results:(1) The growth inhibition of 5-Aza-CdR on HEC-1-B cell line was concentration-dependent and time-dependent and the united group presented a more prominent proapoptotic effects(P0.01),inhibited the cells at G1 period.(2) 5-Aza-CdR can increase the expression of PR-B mRNA by a concentration-dependent manner(P0.01).(3) The hypermethylation of PR-B promoter can be inhibited by 5-Aza-CdR.Conclusions:(1) 5-Aza-CdR combine with progesterone can significant inhibit HEC-1-B cell growth and promote cells apoptosis,and the combination of this two medicine can enhance the effect of MPA on the cell-cycle,block the cells at G1 period.(2) 5-Aza-CdR can renew the expression of PR-B gene,so it can enhance the effect of progesterone.
出处 《现代妇产科进展》 CSCD 北大核心 2011年第8期610-613,617,共5页 Progress in Obstetrics and Gynecology
关键词 子宫内膜肿瘤 5-氮杂脱氧胞苷 醋酸甲羟孕酮 孕激素受体 亚型 甲基化 Endometrial cancer 5-Aza-CdR Medroxyprogesterone Acetate Progesterone receptor Subtype Methylation
  • 相关文献

参考文献14

  • 1Nyholm HC, Christensen IJ, Niclsen AL. Progesterone re- ceplor levels independently predict surviwd in endometrial adenocarcinoma [ J ]. Gynecol Oncol, 1995 ( 3 ) : 59347- 59351.
  • 2Fukuda K, Mori M, Uchiyama M, et al. Prognostic signifi- cance of progesterone receptor immunohistochemistry in endometrial carcinoma [ J ]. Gynecol Oncol, 1998,69 ( 3 ) : 220-225.
  • 3Ehrlich CE, Young PC, Stehman FB, et al. Steroid recep- tors and clinical outcome in patients with adenocarcinoma of the endometrium[ J]. Am J Obstet Gynecol, 1998,158 (4) :796-807.
  • 4Xiong Y, Dowdy SC, Gonzalez Bosquet J, et al. Epigenetic- mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines [ J]. Gynecol Oncol,2005,99 ( 1 ) : 135-141.
  • 5Sadikovic B, AlRomaih K, Squire JA, et al. Cause and con- sequences of genetic and epigenetic alterion in hum an cancer [ J ]. Curr Genomics, 2008,9 (6) : 394-408.
  • 6Salveen HB, MacDonald N, Ryan A, et al. Methylation of MLH1 in a population-based series of endometrial carcino- mas[ J]. Clin Cancer Res,2000 ,6 :3607-3613.
  • 7Simpkins SB, Bocker T, Swisher EM, et al. MLH1 promotor methylation and gene silencing is the primary cause of mi- crosatellite instability in sporadic endometrial cancers [ J ]. Hum Mol Genet, 1999,8:661-666.
  • 8Wong YF, Chung TH, Nobori T, et al. Methylation of p16^INK4A in primary gynecologic malignancy [ J ]. Cancer Lett, 1999,136:231-235.
  • 9Fandy TE. Develpment of DNA methyltransferase inhibi- tors for the treatment of neoplastic diseases [ J ]. Curr Med Chem ,2009,16 ( 17 ) :2075-2085.
  • 10Miremadi A, Oestergaard MZ, Pharoah PD, et al. Cancer genetics of epigenetic genes [ J ]. Hum Mol Genet,2007, 16 : R28-R49.

二级参考文献11

  • 1关志宇,戴冬秋.DNA甲基化与胃肠道肿瘤[J].国外医学(肿瘤学分册),2005,32(2):135-137. 被引量:6
  • 2沈文静,戴冬秋.卵巢癌表遗传学研究进展[J].中华肿瘤防治杂志,2007,14(10):790-794. 被引量:11
  • 3Ibanez de Caceres I.Battagli C,Esteller M,et al.Tumor cell-specific BRCAl and RASSFlA hypermethylation in serum,plasma,and peritoneal fluid from ovarian cancer patients.Cancer Res,2004,64(19):6476-6481.
  • 4Rathi A,Virmani AK,Schorge JO,et al.Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women.Clin Cancer Res,2002,8(11):3324-3331.
  • 5Lund AH,van Lohuizen MV.Epigenetics and cancer.Genes Dev,2004,18(19):2315-2335.
  • 6Makarh PB,Saboorian MH,Ashfaq R,et al.Promoter hyperme-thylation profile of ovarian epithelial neoplasms.Clin Cancer Res,2005,11(15):5365-5369.
  • 7Baylin SB.Reversal of gene silencing as a therapeutic target for cancer-roles for DNA methylation and its interdigitation with chromatin.Novartis Found Symp,2004,259(1):226-233.
  • 8Herman JG,Graff JR,Myohanen S,et al.Methyhtion-spedfic PCP:a novel PCP assay for methylation status of CpG islands.Proc Natl Acad Sci USA,1996,93(16):9821-9826.
  • 9Esteller M.Relevance of DNA methylation in the management of cancer.Lancet Oncol,2003,4(3):351-358.
  • 10Segura PB,Trejo BC,Perez CE,et al.Re-activation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy.Clin Cancer Res,2003,9(5):1596.1603.

共引文献3

同被引文献7

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部